Neubase Therapeutics inc (NBSE)
Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
The company reported operating deficit of $-8.654093 million, in the Sep 30 2022 report
recorded fourth quarter of 2022 operating deficit of $-8.654093 million
Published Dec 22 2022
CSIMarket Team / CSIMarket.com
The Major Pharmaceutical Preparations industry observers begin to analyze the fourth quarter of 2022 numbers. Today those observers observe operating deficit of $-8.654093 million, from the company, as it has not specified any revenue so far, for the respective July to September 30 2022 quarter.
The rising company has not declared the revenue so far, but to place recent effort into a frame of reference. That is supported by measuring with corporate achievement through the fourth quarter of 2021, where the company realized an operating deficit of $-5.895769 million.
On the quest to prompt a lucrative business strategy, businesses often undergo uncommonly rough period. One of this, was the most recent fiscal period, where the net loss has swelled to $-9.668 million.
announced loss of $-33.78 million and revenues of $0.00 million in the fiscal year 2022.
Net loss per share has widen to $-1.04 from $-0.93 in the previous fiscal year, while by 0 % from $0.00 million a year ago.
Neubase Therapeutics Inc is expected to report next financial earnings on May 11, 2023.
The rising company has not declared the revenue so far, but to place recent effort into a frame of reference. That is supported by measuring with corporate achievement through the fourth quarter of 2021, where the company realized an operating deficit of $-5.895769 million.
On the quest to prompt a lucrative business strategy, businesses often undergo uncommonly rough period. One of this, was the most recent fiscal period, where the net loss has swelled to $-9.668 million.
announced loss of $-33.78 million and revenues of $0.00 million in the fiscal year 2022.
Net loss per share has widen to $-1.04 from $-0.93 in the previous fiscal year, while by 0 % from $0.00 million a year ago.
Neubase Therapeutics Inc is expected to report next financial earnings on May 11, 2023.